While functional heterogeneity of fibroblastic cells populating the tumor microenvironment is increasingly recognized, lack of definitive markers complicates elucidation of roles among ostensibly distinctive fibroblastic states. In this issue of Cell, Su et al. characterize a new pro-tumorigenic cancer-associated fibroblast subset mediating chemoresistance defined and driven by a novel signaling pathway.
Various cell types of mesodermal origin, including immune cells, fibroblasts, pericytes, and endothelial cells, contribute to the stromal compartment of the tumor microenvironment (TME) and, in some tumors, can even outnumber the malignant cancer cells. These accessory cells are recruited and/or locally expanded from resident cells, typically evidencing altered or activated phenotypes not found in the normal tissue from which the tumor originated. These corruptions of normal function evidently serve to contribute to tumor development and malignant progression, establishing the concept of tumors as ''outlaw organs'' in which cancer cells and these various accessory cells co-evolve and together contribute to malignancy. While the functional heterogeneity and disparate roles and effects of immune and vascular cells in the tumor stroma have been widely studied, knowledge about other mesenchymal cells and cancer-associated fibroblasts in particular is still incomplete. Contrasting reports have revealed that cancer-associated fibroblasts (CAFs) can have either pro-or anti-tumorigenic roles (Hwang et al., 2008; Olive et al., 2009; Ö zdemir et al., 2014; Rhim et al., 2014) and can originate from bone marrow or local tissue microenvironments, indicating that what has been simplistically summarized as CAFs are in fact assemblages of functionally heterogeneous, possibly even unrelated cell types (or cell states) that can differ both between stages of tumor initiation and progression and among tumor types. In support of this view, Su et al. in this issue of Cell describe a new highly protumorigenic CAF subset in human breast (and non-small cell lung) cancer.
The authors first analyzed the fibroblastoid stroma in a neo-adjuvant clinical study using samples collected before and after debulking chemotherapy in a large cohort of breast cancer patients (Su et al., 2018) . By comparatively profiling CAFs from tumors that were responsive or resistant to chemotherapy, a CAF subset was identified that was preferentially abundant in chemoresistant tumors-one that conveyed the resistant phenotype upon breast cancer cells in co-culture, in co-transplant tumors, and in patient-derived xenograft (PDX) models. While prototypical CAF markers such as a-SMA, PDGFRb, FAP, FSP1, and Collagen 1 are expressed in the CAFs isolated from these tumors, the resistance-supporting subset is distinguished by the expression of the metallo-endopeptidase CD10 (encoded by MME) and the complement anaphylatoxin receptor GPR77 (encoded by C5AR2). The frequency of CD10 + GPR77 + CAFs among all fibroblastic cells in the tumor biopsies was highly variable, ranging from 3% to 92%, and their abundance in breast cancer (and additionally in non-small-cell lung cancer) was associated with worse prognosis and shortened metastasisfree and overall survival.
Loss-of-function genetics revealed a regulatory pathway in which GPR77 is not only a cell-surface marker but also a functional driver of the CAF phenotype. GPR77 is shown to activate ribosomal S6 kinase 1 (RSK1), leading to phosphorylation, acetylation, and activation of NFkB and activation of its target genes IL6 and-in a feed-forward control manner-C5AR2 (and MME). Upregulation of the cytokine IL-6 (as well as IL-8) demonstrably acts to support and increase the abundance of aldehyde dehydrogenase 1 (ALDH1)-positive breast cancer stem cells (CSCs) and consequently the efficiency of tumor initiation in PDX models. Further, the multidrug resistance transporter ABCG2 is induced and is largely responsible for the increased chemoresistance caused by this new CAF subset. The authors suggest that CD10 + GPR77 + CAFs exhibit increased autocrine production of the GPR77 ligand C5a. Upon complement activation, the anaphylatoxin C5a is released by proteolytic cleavage from the complement protein C5, which is produced in the liver. Whether this complement activation follows the classical antibody-mediated pathway or is alternatively the result of spontaneous activation was not addressed. Importantly, a blocking antibody to GPR77 was shown to have therapeutic effect in PDX models, by abrogating this CAF subset and thereby increasing the efficacy of chemotherapy, concomitant with reductions in CSCs. As such, pharmacological disruption of this signaling circuit and the CAF subtype it elicits has promise for combinatorial cancer therapies aimed to abrogate barriers and resistance mechanisms embodied in the TME that limit efficacy of drugs targeting cancer cells (and CSCs). This provocative study raises a number of important questions for future investigation. The prevalence and functional importance of this GPR77 + -driven CAF subtype across the spectrum of human cancers remain to be established. Moreover, while the authors exclude a lineage relationship between CD10 + GPR77 + CAFs and bone marrow-derived mesenchymal stem cells, their origin remains to be defined. Furthermore, it is unclear whether these CAFs correspond to a stable, self-sustained population or to a transitory activation state that can be dynamically reversed to the CAF ''ground state'' that the authors comparatively analyzed. Moreover, it is unclear from the data presented whether the ligand C5a is supplied within bona fide tumors in an autocrine or paracrine fashion and how it is activated from C5 in the TME. Additionally, it is evident that other CAF subtypes populate the tumors analyzed in this study, much as in other tumor types, and their delineation as tumor-promoting, tumorantagonizing, or ambivalent will be of considerable interest. For example a tumor-antagonizing subtype defined by expression of the TGFß inhibitor Asporin has been identified in human breast tumors and associated with good prognosis (Maris et al., 2015) and, as such, warrants comparative assessment. Finally, the role of the cancer cells in establishing this CAF subset remains to be defined. Since these CAFs are present prior to neo-adjuvant therapy, there should exist an inducing event linked to but not necessarily derived directly from the cancer cells.
In conclusion, the report by Su et al. introduces a significant new player to the roster of functionally distinct subsets within the heterogeneous populations of cancer-associated fibroblasts found in tumors (Ö hlund et al., 2017; Brechbuhl et al., 2017) . The continuing definition of the functions, regulation, origins, and plasticity of these cells should improve our ability to diagnose patients at risk and to design more effective combinatorial therapies that leverage knowledge of deleterious versus beneficial roles of CAF subsets in different forms of human cancer.
